MTND5P8: A Potential Drug Target and Biomarker (G100873198)

Target Name: MTND5P8

NCBI ID: G100873198

MTND5P8

Other Name(s): MT-ND5 pseudogene 8

MTND5P8: A Potential Drug Target and Biomarker

Methionine (MT) is a crucial amino acid that plays a vital role in various cellular processes. It is a small molecule that has been linked to various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. MTND5P8, a specific metabolite of MT, has been identified as a potential drug target and biomarker for several diseases.

MTND5P8 is a highly stable metabolite of MT, which is generated by the liver enzyme cytochrome P450 (CYP) 2C9. It has been shown to have a strong binding affinity for several drug targets, including G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a crucial role in cellular signaling.

GPCRs are involved in various physiological processes, including sensory perception, neurotransmitter signaling, and hormone regulation. They are also known to be involved in drug response, as they can interact with a wide range of drugs. Therefore, targeting GPCRs with small molecules such as MTND5P8 could be an effective way to develop new treatments for various diseases.

MTND5P8 has been shown to interact with several GPCRs, including GPCR-CYP2C9 binding sites. This interaction suggests that MTND5P8 could be a useful drug candidate for treating diseases that are characterized by dysfunction in GPCR signaling. For example, MTND5P8 has been shown to interact with the GPCR-CYP2C9 binding site in the breast cancer drug Trastuzumab Emtansine (T-EM), which is used to treat Her2-positive breast cancers.

In addition to its potential use as a drug target, MTND5P8 has also been identified as a potential biomarker for several diseases. The cytochrome P450 enzyme is involved in the metabolism of many drugs, including many statins, which are commonly used to treat hyperlipidemia. Therefore,MTND5P8 could be used as a biomarker for monitoring the effectiveness of statins in treating cardiovascular diseases.

MTND5P8 has been shown to be decreased in patients with hyperlipidemia, a condition characterized by elevated levels of low-density lipoprotein (LDL) cholesterol. This suggests that MTND5P8 may be a useful biomarker for evaluating the effectiveness of statins in treating hyperlipidemia.

MTND5P8 has also been shown to be involved in the metabolism of other drugs, including the anti-inflammatory drug celecoxib. Therefore, it could also be used as a biomarker for monitoring the effects of celecoxib and other drugs used for inflammation.

In conclusion, MTND5P8 is a promising drug target and biomarker that has the potential to revolutionize our understanding of disease. Further studies are needed to fully evaluate its potential in treating various diseases and to determine its safety and efficacy as a drug.

Protein Name: MT-ND5 Pseudogene 8

The "MTND5P8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTND5P8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets